Phase I study of IL-8 inhibitor AMY109 plus atezolizumab (atezo) in patients (pts) with advanced solid tumours

被引：0
|
作者：
Kuboki, Y. [1 ]
Kitano, S. [2 ]
Ikeda, M. [3 ]
Koyama, T. [4 ]
Mizugaki, H. [5 ,6 ]
Narikiyo, T. [7 ]
Yamaguchi, Y. [8 ]
Ishida, T. [9 ]
Takubo, R. [10 ]
Ogami, C. [11 ]
Sekiya, M. [12 ]
Nakagawa, Y. [13 ]
Yamamoto, N. [14 ]
机构：
[1] Natl Canc Ctr Hosp East, Expt Therapeut & GI Oncol Dept, Kashiwa, Chiba, Japan
[2] Canc Inst Hosp JFCR, Canc Immunotherapy Dev Dept, Koto Ku, Tokyo, Japan
[3] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol Dept, Kashiwa, Chiba, Japan
[4] Natl Canc Ctr, Expt Therapeut, Res Inst, Tsukiji Campus,Chuo Ku, Tokyo, Japan
[5] Hokkaido Canc Ctr, Japanese Fdn Canc Res, Canc Inst Hosp, Dept Adv Med Dev, Tokyo, Japan
[6] Canc Inst Hosp JFCR, Tokyo, Japan
[7] Chugai Clin Res Ctr Co Ltd, Clin Study Management Dept, Tokyo, Japan
[8] Chugai Pharmaceut Co Ltd, Early Clin Dev Dept, Fukuoka, Japan
[9] Chugai Pharmaceut Co Ltd, Pharmaceut Sci Dept, Fukuoka, Japan
[10] Chugai Pharmaceut CO LtD, Pharmaceut Sci Dept, Fukuoka, Japan
[11] Chugai Pharmaceut Co Ltd, Pharmaceut Sci Dept, Fukuoka, Japan
[12] Chugai Pharmaceut Co Ltd, Safety Sci Dept, Fukuoka, Japan
[13] Chugai Pharmaceut Co Ltd, Biometr Dept, Chuo Ku, Tokyo, Japan
[14] NCCH Natl Canc Ctr Hosp, Dev Therapeut Dept, Tsukiji Campus,Chuo Ku, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2179
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1040P
引用
下载
收藏
页码：S631 / S632
页数：2
相关论文
共 50 条
  • [1] Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers
    Yamamoto, Noboru
    Kitano, Shigehisa
    Koyama, Takafumi
    Ikeda, Masafumi
    Mizugaki, Hidenori
    Narikiyo, Takatsugu
    Yamaguchi, Yuki
    Ishida, Takaaki
    Takubo, Ryoko
    Ogami, Chika
    Sekiya, Mayuko
    Nakagawa, Yuki
    Kuboki, Yasutoshi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07)
  • [2] A phase I study of tinostamustine in patients (pts) with advanced solid tumours
    Mita, A.
    Loeffler, M.
    Bui, N.
    Remmy, D.
    Mehrling, T.
    Mita, M.
    Rimel, B. J.
    Natale, R. B.
    Kummar, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 177 - +
  • [3] Phase I study of ATN-224 in patients (pts) with advanced solid tumours.
    Lowndes, S. A.
    Adams, A.
    Timms, A.
    Middleton, M.
    Hayward, C.
    Reich, S. D.
    Mazar, A. P.
    Harris, A. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 95S - 95S
  • [4] A phase II study of tinostamustine in patients (pts) with advanced solid tumours
    Tinker, Anna
    Strauss, James Fredric
    Schneider, Reva
    Chugh, Rashmi
    Curigliano, Giuseppe
    Di Nicola, Massimo A.
    Oaknin, Ana
    Janik, Tomas
    Hilgier, Kasia
    Manamley, Nick
    Kummar, Shivaani
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours
    J Martin-Liberal
    M Gil-Martín
    M Sáinz-Jaspeado
    N Gonzalo
    R Rigo
    H Colom
    C Muñoz
    O M Tirado
    X García del Muro
    British Journal of Cancer, 2014, 111 : 858 - 865
  • [6] Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours
    Martin-Liberal, J.
    Gil-Martin, M.
    Sainz-Jaspeado, M.
    Gonzalo, N.
    Rigo, R.
    Colom, H.
    Munoz, C.
    Tirado, O. M.
    Garcia del Muro, X.
    BRITISH JOURNAL OF CANCER, 2014, 111 (05) : 858 - 865
  • [7] PHASE I STUDY OF AFATINIB (BIBW 2992), AN ERBB FAMILY BLOCKER PLUS NINTEDANIB (BIBF 1120), A TRIPLE ANGIOKINASE INHIBITOR, IN PATIENTS (PTS) WITH ADVANCED SOLID TUMOURS
    Soria, J.
    Hollebecque, A.
    Massard, C.
    Deutsch, E.
    Varga, A.
    Morsli, N.
    Kaci, M. Ould
    Staines, H.
    Marzin, K.
    Bahleda, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 155 - 155
  • [8] Phase Ib study of ribociclib (R) plus trametinib (T) in patients (pts) with metastatic/advanced solid tumours
    LoRusso, P.
    Fakih, M.
    De Vos, F. Y. F. L.
    Beck, J. T.
    Merchan, J.
    Shapiro, G.
    Lin, C-C.
    Desai, J.
    Spratlin, J.
    Cascella, T.
    Sandalic, L.
    Abdelhady, A. M.
    Boran, A.
    Gasal, E.
    Janku, F.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S484 - S484
  • [9] Isatuximab (Isa) plus atezolizumab (Atezo) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label multicenter study.
    Vieito Villar, Maria
    Simonelli, Matteo
    Eskens, Ferry A. L. M.
    Gil-Martin, Marta
    Yen, Chia-Jui
    Obermannova, Radka
    Chao, Yee
    Zagonel, Vittorina
    Melichar, Bohuslav
    Moreno, Victor
    Yu, Ming-Lung
    Bongiovanni, Alberto
    Calvo, Emiliano
    Rottey, Sylvie
    Machiels, Jean-Pascal
    Gonzalez-Martin, Antonio
    Paz-Ares, Luis
    Chang, Chih-Long
    Mason, Warren
    Lin, Chia-Chi
    Reardon, David
    Garralda, Elena
    Santoro, Armando
    Meng, Robin
    Abbadessa, Giovanni
    Menas, Fatima
    Lee, Helen
    Liu, Qianying
    Combeau, Cecile
    Ternes, Nils
    Massard, Christophe
    CANCER RESEARCH, 2021, 81 (13)
  • [10] Phase I study of the irreversible FGFR inhibitor (i) futibatinib (FBN; TAS-120) in Japanese patients (pts) with advanced (adv) solid tumours
    Morizane, C.
    Kojima, T.
    Kuboki, Y.
    Bando, H.
    Matsubara, N.
    Shitara, K.
    Yoh, K.
    Hirai, H.
    Kato, T.
    Doi, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S475 - S475
12345